老年非肌层浸润性膀胱癌监测方案的成本效果分析
本研究采用MISCAN微观模拟模型,比较65-85岁非肌层浸润性膀胱癌患者不同监测方案(每3至24个月一次,持续2、5、10年或终生)的成本效果。结果显示,随年龄增长,每患者获得的QALY大幅下降:65岁监测获得2-7个QALY,85岁不足1个QALY;65岁终生每6个月监测的ICER为4999美元/QALY。>75岁患者增加监测频率或时长的QALY增量有限(<2个QALY)。结论支持按年龄制定监测建议。
要点
- 65岁患者监测可获得2-7个QALY,85岁患者不足1个QALY。
- 65岁终生每6个月监测的ICER为4999美元/QALY。
- >75岁患者增加监测频率或时长,QALY增量<2个。
核心结论
- 随年龄增长,复发监测获得的QALY大幅减少,支持按年龄制定NMIBC监测建议。
研究设计与样本
- 采用MISCAN微观模拟模型,比较65-85岁NMIBC患者不同监测方案(每3至24个月一次,持续2、5、10年或终生)的成本效果。
主要发现
- 65岁监测获得2-7个QALY,85岁监测不足1个QALY。
- 监测总成本随年龄增长而下降。
- 65岁终生每6个月监测的ICER为4999美元/QALY。
- >75岁患者增加监测频率或时长的QALY增量<2个。
关键数值与推荐
- ICER计算采用3%贴现率。
- 65岁终生每6个月监测的ICER为4999美元/QALY。
临床怎么用
- 对老年NMIBC患者,尤其>75岁者,可考虑降低监测频率或缩短监测时长以优化成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the cost-effectiveness of surveillance schedules for non-muscle-invasive bladder cancer (NMIBC) amongst older adults. PATIENTS AND METHODS: We developed a MIcrosimulation SCreening ANalysis (MISCAN) microsimulation model to compare the cost-effectiveness of various surveillance schedules (every 3 months to every 24 months, for 2, 5 or 10 years or lifetime) for older adults (aged 65-85 years) with NMIBC. For each surveillance schedule we calculated total costs per patient and the number of quality adjusted life-years (QALYs) gained. Incremental cost-effectiveness ratios (ICERs), as incremental costs per QALY gained, were calculated using a 3% discount. RESULTS: As age increased, the number of QALYs gained per patient decreased substantially. Surveillance of patients aged 65 years resulted in 2-7 QALYs gained, whereas surveillance at age 85 years led to <1 QALY gained. The total costs of the surveillance schedules also decreased as age increased. The ICER of 6-monthly surveillance at age 65 years for lifetime was $4999 (American dollars)/QALY gained. Amongst patients aged >75 years, the incremental yield of QALY gains for any increase in surveillance frequency and/or duration was quite modest (<2 QALYs gained). CONCLUSION: With increasing age, surveillance for recurrences leads to substantially fewer QALYs gained. These data support age-specific surveillance recommendations for patients treated for NMIBC.
引用
- Heijnsdijk EAM, Nieboer D, Garg T, et al. Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer. BJU Int. 2018. PMID: 30066439. doi:10.1111/bju.14502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。